Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.
| Revenue (Most Recent Fiscal Year) | $1.90B |
| Net Income (Most Recent Fiscal Year) | $235.24M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.70 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.32 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 15.85 |
| Pre-Tax Margin (Trailing 12 Months) | -7.35% |
| Net Margin (Trailing 12 Months) | -11.12% |
| Return on Equity (Trailing 12 Months) | -14.88% |
| Return on Assets (Trailing 12 Months) | -5.12% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.02 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.46 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.00 |
| Inventory Turnover (Trailing 12 Months) | 0.59 |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.63 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-3.84 |
| Earnings per Share (Most Recent Fiscal Year) | $2.34 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.69 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 98.28M |
| Free Float | 90.71M |
| Market Capitalization | $3.79B |
| Average Volume (Last 20 Days) | 5.80M |
| Beta (Past 60 Months) | 0.85 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.68% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |